Next Article in Journal
Childhood Leukemia Survivors and Metabolic Response to Exercise: A Pilot Controlled Study
Next Article in Special Issue
Lower Plasma Melatonin Levels Predict Worse Long-Term Survival in Pulmonary Arterial Hypertension
Previous Article in Journal
Fluorescent Light Energy (FLE) Acts on Mitochondrial Physiology Improving Wound Healing
Previous Article in Special Issue
The Clinical Impact of Flow Titration on Epoprostenol Delivery via High Flow Nasal Cannula for ICU Patients with Pulmonary Hypertension or Right Ventricular Dysfunction: A Retrospective Cohort Comparison Study
Review

Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective

Department of Pulmonary Medicine, Erasmus MC, Doctor Molenwaterplein 40, 3015 GD Rotterdam, The Netherlands
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
J. Clin. Med. 2020, 9(2), 561; https://doi.org/10.3390/jcm9020561
Received: 14 December 2019 / Revised: 10 February 2020 / Accepted: 16 February 2020 / Published: 19 February 2020
Pulmonary hypertension (PH) is a debilitating progressive disease characterized by increased pulmonary arterial pressures, leading to right ventricular (RV) failure, heart failure and, eventually, death. Based on the underlying conditions, PH patients can be subdivided into the following five groups: (1) pulmonary arterial hypertension (PAH), (2) PH due to left heart disease, (3) PH due to lung disease, (4) chronic thromboembolic PH (CTEPH), and (5) PH with unclear and/or multifactorial mechanisms. Currently, even with PAH-specific drug treatment, prognosis for PAH and CTEPH patients remains poor, with mean five-year survival rates of 57%–59% and 53%–69% for PAH and inoperable CTEPH, respectively. Therefore, more insight into the pathogenesis of PAH and CTEPH is highly needed, so that new therapeutic strategies can be developed. Recent studies have shown increased presence and activation of innate and adaptive immune cells in both PAH and CTEPH patients. Moreover, extensive biomarker research revealed that many inflammatory and immune markers correlate with the hemodynamics and/or prognosis of PAH and CTEPH patients. Increased evidence of the pathological role of immune cells in innate and adaptive immunity has led to many promising pre-clinical interventional studies which, in turn, are leading to innovative clinical trials which are currently being performed. A combination of immunomodulatory therapies might be required besides current treatment based on vasodilatation alone, to establish an effective treatment and prevention of progression for this disease. In this review, we describe the recent progress on our understanding of the involvement of the individual cell types of the immune system in PH. We summarize the accumulating body of evidence for inflammation and immunity in the pathogenesis of PH, as well as the use of inflammatory biomarkers and immunomodulatory therapy in PAH and CTEPH. View Full-Text
Keywords: pulmonary arterial hypertension; chronic thromboembolic pulmonary hypertension; inflammation and immunity; circulating inflammatory biomarkers; immunomodulatory therapy pulmonary arterial hypertension; chronic thromboembolic pulmonary hypertension; inflammation and immunity; circulating inflammatory biomarkers; immunomodulatory therapy
Show Figures

Figure 1

MDPI and ACS Style

Koudstaal, T.; Boomars, K.A.; Kool, M. Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective. J. Clin. Med. 2020, 9, 561. https://doi.org/10.3390/jcm9020561

AMA Style

Koudstaal T, Boomars KA, Kool M. Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective. Journal of Clinical Medicine. 2020; 9(2):561. https://doi.org/10.3390/jcm9020561

Chicago/Turabian Style

Koudstaal, Thomas, Karin A. Boomars, and Mirjam Kool. 2020. "Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective" Journal of Clinical Medicine 9, no. 2: 561. https://doi.org/10.3390/jcm9020561

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop